BRAF and melanoma: In patients with stage III melanoma with BRAF V600E or V600K mutations, the phase III COMBI-AD trial demonstrated that adjuvant dabrafenib plus trametinib significantly improved relapse-free survival and overall survival compared with placebo at three and five years of follow-up [43].